

Please amend page 27, line 1 as follows:

Claims What is claimed is:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceuticals characterized by general formula (I)



wherein

V denotes a peptide with a binding sequence $-X^1-X^2-\text{Val-Tyr-Ile-His-Pro-}X^8-X^9-X^{10}$,

SEQ ID NO. 1

L denotes bond or a linker,

Z denotes a group that optionally can carry an imaging moiety M,

X^1 denotes $-\text{NY}_1-(\text{CH}_2)_m-\text{CO}-$ where m is an integer from 1 to 10 and Y_1 is H or an alkyl or aryl containing substituent,

X^2 denotes Arg, N-alkylated Arg, a Arg mimetics Phe[4-guanidino] or Gly-4-piperidyl[N-amidino],

X^8 denotes Gly, Phe, Phg, Hph, Bip, Ala, Tyr, His, Trp or Nal, SEQ ID NO. 1

X^9 and X^{10} denote, independent of each other, Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys SEQ ID NO. 1 and where X^8 , X^9 and X^{10} together constitute an ACE cleavage site

and wherein the residues Val and Ile at position 3 and 5 respectively may optionally be replaced with amino acids capable of forming a bridging unit wherein the bridge containing a $-\text{CH}_2-\text{CH}_2-$, $-\text{S}-\text{CH}_2-$, $-\text{S}-\text{CH}_2-\text{S}-$, lactam or $-\text{S}-\text{S}-$ unit,

Z forms a bond with the amino acid X^1 optionally through the linker L, and

M where present denotes an imageable moiety capable of detection either directly or indirectly in a diagnostic imaging procedure.

2. (Currently amended) A pharmaceutical according to claim 1 wherein the amino acid of X^1 , X^2 , X^8 , X^9 , X^{10} are independently selected from

X^1 denoting Gly

X^2 denoting Arg or N-Methyl-Arg

X^8 denoting Phe


X^9 denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys SEQ ID NO. 1 and

X^{10} denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys SEQ ID NO. 1.

3. (Currently amended) A pharmaceutical according to ~~the preceding claims~~ claim 1 further comprising one or more biomodifier groups are attached to any positions of the V and L groups of formula (I)

4. (Currently amended) A pharmaceutical according to ~~the preceding claims~~ claim 1 wherein Z denotes a chelating agent.

5. (Original) A pharmaceutical according to claim 4 wherein Z denotes the chelating agent of formula (VII)



(VII)

wherein:

each R¹, R², R³ and R⁴ is independently H or C₁₋₁₀ alkyl, C₃₋₁₀ alkylaryl, C₂₋₁₀ alkoxyalkyl, C₁₋₁₀ hydroxyalkyl, C₁₋₁₀ alkylamine, C₁₋₁₀ fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

6. (Currently amended) A pharmaceutical according to ~~any of the preceding claims~~ claim 5 wherein M represents an imageable moiety for the use in diagnosis particularly in *in vivo* diagnosis comprising a moiety which emit or cause to emit detectable radiation, a moiety which affect local electromagnetic fields, moieties which absorb or scatter radiation energy, heavy metals and compounds thereof and moieties which generate a detectable substance.

7. (Original) A pharmaceutical according to claim 6 wherein M represents a gamma emitting moiety for Radio or SPECT imaging comprising ⁶⁷Ga, ¹¹¹In, ¹²³I, ¹²⁵I, ¹³¹I, ^{81m}Kr, ⁹⁹Mo, ^{99m}Tc, ²⁰¹Tl and ¹³³Xe.

8. (Original) A pharmaceutical according to claim 6 wherein M represents a radio emitter with positron emitting properties for PET imaging comprising ¹¹C, ¹⁸F, ⁶⁸Ga, ¹³N, ¹⁵O and ⁸²Rb.

9. (Currently amended) A pharmaceuticals according to ~~claims 1 to 5~~ claim 1 characterized by general formula (I)

Z-L-V (I)

wherein

V denotes a peptide with a binding sequence $-X^1-X^2\text{-Val-Tyr-Ile-His-Pro-}X^8\text{-}X^9\text{-}X^{10}$, SEQ ID NO. 1 wherein the amino acid of X^1 , X^2 , X^8 , X^9 , X^{10} are independently selected from

X^1 denoting Gly


X^2 denoting Arg or N-Methyl-Arg

X^8 denoting Phe


X^9 denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys SEQ ID NO. 1 and

X^{10} denoting Pro, Arg, His, Ala, Phe, Glu, Leu, Val, Ile, Met, Trp, Asp or Lys SEQ ID NO. 1.


L denotes a bond or a linker selected from compounds of formula $\text{NH}-(\text{CH}_2)_m\text{-}$ optionally combined with $-\text{CO}-(\text{CH}_2)_m\text{-CO-}$ where m denotes a positive integer from 1 to 10, one or more units of compounds of formula (IV) wherein n is an integer from 1 to 10, compounds of formula (X) or (VI)



Formula (IV)




Formula (X)



Formula (VI)

Z denotes a chelating agent of formula (VII) that optionally can carry an imaging moiety M, and one or more biomodifier groups selected from monodisperse PEG building block comprising 1 to 10 units of said building block or the compound of formula IV,



Formula (IV)

wherein n equals an integer from 1 to 10 are attached to any positions of the V and L groups of formula (I).

10. (Original) Pharmaceutical formulation comprising a pharmaceutical of formula (I) of claim 1 together with one or more pharmaceutical acceptable additives and/or excipients.

11. (Original) A kit for the preparation of a radiopharmaceutical composition of formula (I) comprising a peptide-chelate conjugate and a reducing agent.